Radnostix reports 27% Q1 revenue decline

Radnostix reported total revenue of $2.38M for the first quarter of 2026, down 27% from $3.24M in the same period of 2025. The quarter ended March 31.

Recall impacts, isotope shortages, and Cobalt-60 downtime drove the revenue decline, according to the company. Radnostix, formerly International Isotopes, manufactures radioisotope-focused products for medical, industrial, and research applications.

Gross profit fell 43% to $1.15M from $2.03M in the prior-year period. Radnostix attributed the decrease to recall impacts and changes in labor cost allocation.

Net loss widened to $1.35M, compared with a net loss of about $112,700 in Q1 2025. Adjusted EBITDA declined to -$0.92M from $0.12M, while operating expenses rose 7% to $2.46M.

During the quarter, Radnostix completed construction of a dedicated Calibration & Reference Products manufacturing facility and received an initial U.S. Nuclear Regulatory Commission license amendment for the site. The company said the facility is intended to support capacity expansion and product portfolio growth in 2026.

Commercial activity related to the Cobalt-60 hot cell resumed during Q1 after more than 5 months of downtime. Radnostix said the repair and retrofit work extended the asset’s useful life by 15 to 20 years.

Cash and cash equivalents stood at $1.35M at quarter-end, down from $1.70M on Dec. 31, 2025. Net cash used in operating activities was $72,442 for the quarter.

Radnostix operates across theranostics, nuclear medicine, industrial isotope applications, and radiation safety. Its investor materials describe the company as a supplier to hospitals, radiopharmacies, imaging centers, and research institutions.